$NNVC
NANOVIRICIDES, INC. Stock $nnvc

$nnvc Overview Financials Valuation SEC Filings Company Website

2022 Q2 Form 10-Q Financial Statement

#000141057822001688 Filed on May 16, 2022

Income Statement

Concept	2022 Q2	2022 Q1	2021 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$621.2K	$532.8K	$659.3K
YoY Change	26.74%	-17.18%	-17.46%
% of Gross Profit
Research & Development	$1.172M	$1.255M	$1.261M
YoY Change	-26.04%	-14.28%	-15.53%
% of Gross Profit
Depreciation & Amortization	$188.0K	$179.5K	$175.3K
YoY Change	6.69%	3.11%	1.38%
% of Gross Profit
Operating Expenses	$1.793M	$1.788M	$1.921M
YoY Change	-13.57%	-15.17%	-16.2%
Operating Profit		-$1.788M	-$1.921M
YoY Change		-15.17%	-16.2%
Interest Expense	$12.79K	$4.789K	$2.631K
YoY Change	820.14%	867.47%	-92.95%
% of Operating Profit
Other Income/Expense, Net		-$4.789K	-$558.00
YoY Change		867.47%	-98.54%
Pretax Income	-$1.780M	-$1.793M	-$1.921M
YoY Change	-14.13%	-14.96%	-17.55%
Income Tax	$0.00		$0.00
% Of Pretax Income
Net Earnings	-$1.780M	-$1.793M	-$1.921M
YoY Change	-14.13%	-14.96%	-17.55%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.16	-$0.17
Diluted Earnings Per Share	-$154.0K	-$0.16	-$0.17
COMMON SHARES
Basic Shares Outstanding	11.55M	11.54M	11.53M
Diluted Shares Outstanding		11.54M	11.53M

Balance Sheet

Concept	2022 Q2	2022 Q1	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$14.07M	$15.57M	$17.34M
YoY Change	-31.44%	-32.0%	-5.75%
Cash & Equivalents	$14.10M	$15.60M	$17.30M
Short-Term Investments
Other Short-Term Assets	$350.0K	$374.6K	$179.3K
YoY Change	13.98%	12.98%	90.15%
Inventory
Prepaid Expenses	$350.0K	$337.2K	$141.9K
Receivables
Other Receivables
Total Short-Term Assets	$14.42M	$15.95M	$17.52M
YoY Change	-30.77%	-31.36%	-5.26%
LONG-TERM ASSETS
Property, Plant & Equipment	$8.694M	$8.805M	$8.945M
YoY Change	-4.3%	-4.03%	-3.17%
Goodwill
YoY Change
Intangibles	$341.8K	$343.9K	$346.0K
YoY Change	-2.36%
Long-Term Investments
YoY Change
Other Assets	$42.44K	$49.22K	$3.520K
YoY Change	1105.68%	1298.3%	-39.83%
Total Long-Term Assets	$9.078M	$9.198M	$9.294M
YoY Change	-3.81%	-3.49%	-3.16%
TOTAL ASSETS
Total Short-Term Assets	$14.42M	$15.95M	$17.52M
Total Long-Term Assets	$9.078M	$9.198M	$9.294M
Total Assets	$23.49M	$25.14M	$26.81M
YoY Change	-22.36%	-23.25%	-4.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$272.4K	$196.6K	$320.1K
YoY Change	17.62%	-71.15%	1.94%
Accrued Expenses	$45.69K	$25.25K	$24.16K
YoY Change	88.15%	4.22%	-4.37%
Deferred Revenue
YoY Change
Short-Term Debt	$94.79K	$164.9K	$0.00
YoY Change	-0.55%	-0.54%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$412.8K	$386.7K	$344.3K
YoY Change	17.57%	-55.62%	1.47%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$412.8K	$386.7K	$344.3K
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$412.8K	$386.7K	$344.3K
YoY Change	17.57%	-55.62%	1.47%
SHAREHOLDERS EQUITY
Retained Earnings	-$122.5M	-$121.0M	-$119.0M
YoY Change	7.09%
Common Stock	$11.59K	$11.55K	$11.53K
YoY Change	0.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$23.08M	$24.76M	$26.47M
YoY Change
Total Liabilities & Shareholders Equity	$23.49M	$25.14M	$26.81M
YoY Change	-22.36%	-23.25%	-4.54%

Cashflow Statement

Concept	2022 Q2	2022 Q1	2021 Q4
OPERATING ACTIVITIES
Net Income	-$1.780M	-$1.793M	-$1.921M
YoY Change	-14.13%	-14.96%	-17.55%
Depreciation, Depletion And Amortization	$188.0K	$179.5K	$175.3K
YoY Change	6.69%	3.11%	1.38%
Cash From Operating Activities	-$1.398M	-$1.655M	-$2.114M
YoY Change	-37.26%	15.36%	-8.69%
INVESTING ACTIVITIES
Capital Expenditures	-$75.36K	-$39.33K	-$185.4K
YoY Change	-10.96%	-64.42%	2060.26%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$75.36K	-$39.33K	-$185.4K
YoY Change	-10.96%	-64.42%	2060.26%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-32.71K	-69.30K	-61.37K
YoY Change	-53.6%	-101.15%	-94.29%
NET CHANGE
Cash From Operating Activities	-1.398M	-1.655M	-2.114M
Cash From Investing Activities	-75.36K	-39.33K	-185.4K
Cash From Financing Activities	-32.71K	-69.30K	-61.37K
Net Change In Cash	-1.506M	-1.764M	-2.361M
YoY Change	-36.81%	-139.14%	-30.54%
FREE CASH FLOW
Cash From Operating Activities	-$1.398M	-$1.655M	-$2.114M
Capital Expenditures	-$75.36K	-$39.33K	-$185.4K
Free Cash Flow	-$1.322M	-$1.616M	-$1.929M
YoY Change	-38.3%	22.02%	-16.39%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
	dei	Local Phone Number LocalPhoneNumber	937-6137
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.55
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.63
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11540926
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10953052
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11527069
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10700405
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
	dei	Entity Central Index Key EntityCentralIndexKey	0001379006
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	0
CY2022Q1	us-gaap	Accrued Royalties Current And Noncurrent AccruedRoyaltiesCurrentAndNoncurrent	0
CY2021Q2	us-gaap	Accrued Royalties Current And Noncurrent AccruedRoyaltiesCurrentAndNoncurrent	0
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CT
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
	dei	Entity File Number EntityFileNumber	001-36081
	dei	Entity Registrant Name EntityRegistrantName	NANOVIRICIDES, INC.
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	76-0674577
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1 Controls Drive
	dei	Entity Address City Or Town EntityAddressCityOrTown	Shelton
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	06484
	dei	City Area Code CityAreaCode	203
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
	dei	Security12b Title Security12bTitle	Common Stock
	dei	Trading Symbol TradingSymbol	NNVC
	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	11554000
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15572134
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20516677
CY2022Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	337182
CY2021Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	307102
CY2022Q1	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	37408
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	2107535
	us-gaap	Operating Expenses OperatingExpenses	6320816
	us-gaap	Operating Expenses OperatingExpenses	6669840
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1464177
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4613302
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4530448
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Assets Current AssetsCurrent	15946724
CY2021Q2	us-gaap	Assets Current AssetsCurrent	20823779
CY2022Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	14582652
CY2021Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	14333666
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5777932
CY2021Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5248765
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8804720
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9084901
CY2022Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	458954
CY2021Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	458954
CY2022Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	115038
CY2021Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	108836
CY2022Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	343916
CY2021Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	350118
CY2022Q1	nnvc	Service Agreements ServiceAgreements	45702
CY2022Q1	us-gaap	Security Deposit SecurityDeposit	3515
CY2021Q2	us-gaap	Security Deposit SecurityDeposit	3515
CY2022Q1	us-gaap	Other Assets OtherAssets	49217
CY2021Q2	us-gaap	Other Assets OtherAssets	3515
CY2022Q1	us-gaap	Assets Assets	25144577
CY2021Q2	us-gaap	Assets Assets	30262313
CY2022Q1	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	122987
CY2021Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	200016
CY2022Q1	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	73587
CY2021Q2	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	31539
CY2022Q1	us-gaap	Loans Payable LoansPayable	164905
CY2021Q2	us-gaap	Loans Payable LoansPayable	95306
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	25252
CY2021Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	24285
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	386731
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	351146
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11554476
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11515170
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	11554
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	11515
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	145457987
CY2021Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	144284593
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-120712179
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-114385313
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	24757846
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	29911167
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	25144577
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	30262313
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1255074
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	643358
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	532801
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1707514
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2139392
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	1787875
	us-gaap	Interest Expense InterestExpense	77471
	us-gaap	Interest Expense InterestExpense	6050
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1787875
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2107535
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6320816
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6669840
CY2022Q1	us-gaap	Interest Expense InterestExpense	4789
CY2021Q1	us-gaap	Interest Expense InterestExpense	495
CY2022Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0
CY2021Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-2026
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4789
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-495
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6050
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-79477
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-1792664
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-2108030
	us-gaap	Net Income Loss NetIncomeLoss	-6326866
	us-gaap	Net Income Loss NetIncomeLoss	-6749317
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.55
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.63
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11540926
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10953052
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11527069
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10700405
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	29911167
CY2021Q3	nnvc	Series Preferred Shares Issued During Period Employee Stock Compensation Value Issued SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued	32890
CY2021Q3	nnvc	Series Preferred Shares Value Issued During Period For License Agreement SeriesPreferredSharesValueIssuedDuringPeriodForLicenseAgreement	935088
CY2021Q3	nnvc	Stock Issued During July Value Issued For Share Based Compensation Consulting And Legal Service One StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne	27000
CY2021Q3	nnvc	Stock Issued During Shares Issued For Share Based Compensation Consulting And Legal Services StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServices	1352
CY2021Q3	nnvc	Stock Issued For Payment Of Director Fees Value StockIssuedForPaymentOfDirectorFeesValue	15000
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-2613068
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	28309429
CY2021Q4	nnvc	Series Preferred Shares Value Issued During Period For License Agreement SeriesPreferredSharesValueIssuedDuringPeriodForLicenseAgreement	33367
CY2021Q4	nnvc	Stock Issued During July Value Issued For Share Based Compensation Consulting And Legal Service One StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne	27000
CY2021Q4	nnvc	Stock Issued During Shares Issued For Share Based Compensation Consulting And Legal Services StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServices	1644
CY2021Q4	nnvc	Stock Issued For Payment Of Director Fees Value StockIssuedForPaymentOfDirectorFeesValue	15000
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-1921134
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	26465306
CY2022Q1	nnvc	Series Preferred Shares Issued During Period Employee Stock Compensation Value Issued SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued	39401
CY2022Q1	nnvc	Stock Issued During July Value Issued For Share Based Compensation Consulting And Legal Service One StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne	27000
CY2022Q1	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	6768
CY2022Q1	nnvc	Stock Issued During Shares Issued For Share Based Compensation Consulting And Legal Services StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServices	785
CY2022Q1	nnvc	Stock Issued For Payment Of Director Fees Value StockIssuedForPaymentOfDirectorFeesValue	11250
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-1792664
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	24757846
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	21757962
CY2020Q3	nnvc	Series Preferred Shares Issued During Period Employee Stock Compensation Value Issued SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued	53098
CY2020Q3	nnvc	Stock Issued During July Value Issued For Share Based Compensation Consulting And Legal Service One StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne	27000
CY2020Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10442216
CY2020Q3	nnvc	Stock Issued During Shares Issued For Share Based Compensation Consulting And Legal Services StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServices	1986
CY2020Q3	nnvc	Stock Issued For Payment Of Director Fees Value StockIssuedForPaymentOfDirectorFeesValue	11250
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-2311233
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	29982279
CY2020Q4	nnvc	Series Preferred Shares Issued During Period Employee Stock Compensation Value Issued SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued	50602
CY2020Q4	nnvc	Stock Issued During July Value Issued For Share Based Compensation Consulting And Legal Service One StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne	27000
CY2020Q4	nnvc	Stock Issued During Shares Issued For Share Based Compensation Consulting And Legal Services StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServices	1215
CY2020Q4	nnvc	Stock Issued For Payment Of Director Fees Value StockIssuedForPaymentOfDirectorFeesValue	15000
CY2020Q4	us-gaap	Net Income Loss NetIncomeLoss	-2330054
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	27746042
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	6121481
CY2021Q1	nnvc	Series Preferred Shares Issued During Period Employee Stock Compensation Value Issued SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued	71500
CY2021Q1	nnvc	Stock Issued During July Value Issued For Share Based Compensation Consulting And Legal Service One StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne	27000
CY2021Q1	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	15038
CY2021Q1	nnvc	Stock Issued During Shares Issued For Share Based Compensation Consulting And Legal Services StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServices	1750
CY2021Q1	nnvc	Stock Issued For Payment Of Director Fees Value StockIssuedForPaymentOfDirectorFeesValue	15000
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-2108030
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	31889781
	us-gaap	Profit Loss ProfitLoss	-6326866
	us-gaap	Profit Loss ProfitLoss	-6749317
	nnvc	Preferred Shares Issued As Compensation PreferredSharesIssuedAsCompensation	105658
	nnvc	Preferred Shares Issued As Compensation PreferredSharesIssuedAsCompensation	175200
	nnvc	Preferred Shares Issued For License Agreement PreferredSharesIssuedForLicenseAgreement	935088
	nnvc	Preferred Shares Issued For License Agreement PreferredSharesIssuedForLicenseAgreement	0
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	129018
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	137288
	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	3781
	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	4951
	us-gaap	Depreciation Depreciation	529167
	us-gaap	Depreciation Depreciation	522172
	nnvc	Amortization Of Loan Origination Fees AmortizationOfLoanOriginationFees	0
	nnvc	Amortization Of Loan Origination Fees AmortizationOfLoanOriginationFees	18013
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6202
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6202
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-2026
	nnvc	Written Off Financing Costs Classified As Operating Activities WrittenOffFinancingCostsClassifiedAsOperatingActivities	0
	nnvc	Written Off Financing Costs Classified As Operating Activities WrittenOffFinancingCostsClassifiedAsOperatingActivities	12190
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-204118
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-180988
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	45702
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-10158
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-77029
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-282492
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	42048
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	21495
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	967
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-45012
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4493550
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5986138
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	248986
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	154122
	nnvc	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	0
	nnvc	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	16563697
	nnvc	Payment Of Note Payable Related Party PaymentOfNotePayableRelatedParty	0
	nnvc	Payment Of Note Payable Related Party PaymentOfNotePayableRelatedParty	1100000
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	37408
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0
	nnvc	Payment Of Loans Payable PaymentOfLoansPayable	164599
	nnvc	Payment Of Loans Payable PaymentOfLoansPayable	132513
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-202007
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15331184
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-4944543
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	9190924
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20516677
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13708594
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15572134
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22899518
	us-gaap	Interest Paid Net InterestPaidNet	3488
	us-gaap	Interest Paid Net InterestPaidNet	3171
	nnvc	Directors And Officers Insurance Financed Through Loan DirectorsAndOfficersInsuranceFinancedThroughLoan	234198
	nnvc	Directors And Officers Insurance Financed Through Loan DirectorsAndOfficersInsuranceFinancedThroughLoan	235476
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Note 1 – Organization and Nature of Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">NanoViricides, Inc. (the “Company”) is a nano-biopharmaceutical research and development company specializing in the discovery, development, and commercialization of drugs to combat viral infections using its unique and novel nanomedicines technology. NanoViricides is also unique in the bio-pharma field in that it possesses its own state of the art facilities for the design, synthesis, analysis and characterization of the nanomedicines that the Company develops, as well as for production scale-up, and c-GMP-like production in quantities needed for human clinical trials, where the Company’s design, development, and production work is performed. The biological studies such as the effectiveness, safety, bio-distribution and Pharmacokinetics/Pharmacodynamics on the Company’s drug candidates are performed by external collaborators and contract organizations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company has several drugs in various stages of early development. COVID-19 has become the Company’s lead drug program due to the necessity of responding to the pandemic. The Company began development of a drug to treat COVID-19 patients just as the cases of the novel disease were being reported from China. The Company’s drug candidates for COVID-19 successfully entered core safety pharmacology studies required prior to any human clinical trials around October/November, 2020. The studies were completed in January and February 2021, and the Company had received, at that time, draft reports from the external Contract Research Organization (CRO). The final quality audited reports on these studies have been signed and released to the Company. These cGLP core safety pharmacology reports are required for an Investigational New Drug (IND) Application. The Company is currently working on a pre-IND application to the US Food and Drug Administration (FDA) to seek guidance for an IND. The Company is also involved with tasks needed for setting up and executing human clinical trials for the Company’s COVID-19 drug candidates, including selection of a Clinical Trial Contract Research Organization. In addition to the FDA, the Company is also seeking to obtain regulatory approvals from other international bodies in order to perform the clinical trials in countries other than the USA. The Company cannot provide a timeline at this point because of external dependencies in the filing of regulatory applications, their approval(s) and beginning of clinical trials. There are 15 COVID-19 drugs that have received Emergency Use Authorization (EUA) and one drug that has received full approval (remdesivir) from the FDA (https://www.fda.gov/drugs/coronavirus-covid-19-drugs/coronavirus-treatment-acceleration-program-ctap#dashboard). In addition, there are at least three vaccines licensed in the USA and several more are in use internationally. Apart from remdesivir and antibodies, there are very few drugs with direct antiviral effect that have EUA or are in clinical trials. Internationally, virus variants have continued to emerge with resistance to drugs and vaccines. Scientists believe it is only a matter of time before resistant variants against existing vaccines and therapeutics become commonplace. Thus the need for therapeutics that the virus would not escape by mutations, such as the broad-spectrum, pan-coronavirus nanoviricides drug candidates, remains unmet. Additionally, specific populations such as immune-compromised persons, HIV-positive persons, and others would require therapeutics even if they are fully vaccinated, as the weak immune system in these populations limits the ability of vaccines to protect from COVID-19 infection and disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company plans on re-engaging its other lead antiviral program against herpes viruses, i.e. the HerpeCide™ program, as soon as it becomes feasible to conduct the corresponding antiviral human clinical studies. In the HerpeCide program alone, the Company has drug candidates against at least five indications at different stages of development. Of these, the Company is advancing the shingles drug candidate towards human clinical trials. The IND-enabling Safety/Toxicology studies required for doing so have been completed and the Company was in the process of preparing an IND application for this drug candidate when the SRAS-CoV-2 virus struck, whereupon management pivoted its efforts to respond to the threat of what has now become the COVID-19 pandemic. In addition, the Company’s drug candidates against HSV-1 “cold sores” and HSV-2 “genital herpes” are in advanced studies and are expected to follow the shingles drug candidate into human clinical trials. Shingles in adults and chicken pox in children is caused by the same virus, namely VZV (Varicella-zoster virus, aka HHV-3 or human herpesvirus-3). There are estimated to be approximately 120,000-150,000 annual chickenpox cases in the USA in the post-vaccination-era, i.e. since childhood vaccination with the live attenuated varicella virus Oka strain has become standard. In addition, the Company has drugs in development against all influenzas in our FluCide™ program, as well as drug candidates against HIV/AIDS, Dengue, Ebola/Marburg, and other viruses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company’s drugs are based on several patents, patent applications, provisional patent applications, and other proprietary intellectual property held by TheraCour Pharma, Inc. (“TheraCour”), to which the Company has broad, exclusive licenses. The first license agreement the Company executed with TheraCour on September 1, 2005 (“Exclusive License Agreement”), gave the Company an exclusive, worldwide license for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex Virus (HSV), Influenza and Asian Bird Flu Virus. On February 15, 2010, the Company executed an Additional License Agreement with TheraCour. Pursuant to the Additional License Agreement, the Company was granted exclusive licenses for technologies, developed by TheraCour, for the development of drug candidates for the treatment of Dengue viruses, Ebola/Marburg viruses, Japanese Encephalitis, viruses causing viral Conjunctivitis (a disease of the eye) and Ocular Herpes. In addition, on November 1, 2019, the Company entered into a world-wide, exclusive, sub-licensable, license (“VZV License Agreement”) to use, promote, offer for sale, import, export, sell and distribute drugs that treat VZV infections, using TheraCour’s proprietary as well as patented technology and intellectual property. The discovery of ligands and polymer materials as well as formulations, the chemistry and chemical characterization, as well as process development and related work will be performed by TheraCour under the same compensation terms as prior agreements between the parties, with no duplication of costs allowed. Upon commercialization, NanoViricides will pay 15% of net sales to TheraCour, as defined in the agreement. The Company was not required to make any upfront payments to TheraCour and agreed to the following milestone payments to TheraCour; the issuance of 75,000 shares of the Company’s Series A preferred stock upon the grant of an IND Application; $1,500,000 in cash upon completion of Phase I Clinical Trials; $2,500,000 in cash upon completion of Phase II clinical trials; and $5,000,000 in cash upon completion of Phase III clinical trials. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 9, 2021, the Company entered into a world-wide, exclusive, sub-licensable, license (“Covid-19 License Agreement”) to use, promote, offer for sale, import, export, sell and distribute drugs that treat Covid-19 infections, using TheraCour’s proprietary as well as patented technology and intellectual property. The discovery of ligands and polymer materials as well as formulations, the chemistry and chemical characterization, as well as process development and related work will be performed by TheraCour under the same compensation terms as prior agreements between the parties, with no duplication of costs allowed. Upon commercialization, NanoViricides will pay 15% of net sales to TheraCour, as defined in the agreement. The Company was not required to make any upfront cash payments to TheraCour and agreed to the following milestone payments to TheraCour: (i) the issuance of 100,000 shares of the Company’s Series A preferred stock within 30 days upon execution of this agreement; (ii) the issuance of 50,000 shares of the Company’s Series A preferred stock upon the approval of the Company's IND Application or its equivalent by a competent regulatory authority; (iii) $1,500,000 upon initiation of Phase I clinical trials, or its equivalent, for at least one licensed product within-the field on, or before, three (3) months from the date of the authority’s acceptance of the IND, or its equivalent; (iv) $2,000,000 in cash upon completion of Phase 1 clinical trials; (v) $2,500,000 in cash upon completion of Phase IIA clinical trials, or, its equivalent; (vi) the issuance of 100,000 shares of the Company’s Series A preferred stock upon the initiation of Phase 3 clinical trials, or, its equivalent, for at least one licensed product within the field; and (vii) $5,000,000 in cash, or 500,000 shares of the Company’s Series A preferred stock upon completion of Phase III clinical trials, or its equivalent. Upon commercialization, NanoViricides will pay 15% of net sales to TheraCour, as defined in the agreement.</p>
CY2019Q4	nnvc	Stock Issued During Period Value New Issues Cash Upon Completion Of Phase1 Clinical Trials StockIssuedDuringPeriodValueNewIssuesCashUponCompletionOfPhase1ClinicalTrials	1500000
CY2019Q4	nnvc	Stock Issued During Period Value New Issues Cash Upon Completion Of Phase2 Clinical Trials StockIssuedDuringPeriodValueNewIssuesCashUponCompletionOfPhase2ClinicalTrials	2500000
CY2019Q4	nnvc	Stock Issued During Period Value New Issues Cash Upon Completion Of Phase3 Clinical Trials StockIssuedDuringPeriodValueNewIssuesCashUponCompletionOfPhase3ClinicalTrials	5000000
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-121000000
	us-gaap	Net Income Loss NetIncomeLoss	-6300000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4500000
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15600000
CY2022Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	14582652
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9146
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14146
	nnvc	Percentage Of Direct Costs PercentageOfDirectCosts	0.30
	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	2000
CY2022Q1	nnvc	Debt Instrument Interest Payable Escrowed DebtInstrumentInterestPayableEscrowed	132000
CY2021Q1	nnvc	Interest Expense Which Reduced Interest Escrow Deposit Retained By Lender Amount InterestExpenseWhichReducedInterestEscrowDepositRetainedByLenderAmount	0
	nnvc	Interest Expense Which Reduced Interest Escrow Deposit Retained By Lender Amount InterestExpenseWhichReducedInterestEscrowDepositRetainedByLenderAmount	62773
CY2022Q1	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	8149416
CY2021Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	8020471
CY2022Q1	us-gaap	Land Land	260000
CY2021Q2	us-gaap	Land Land	260000
CY2022Q1	nnvc	Office Equipment Gross OfficeEquipmentGross	57781
CY2021Q2	nnvc	Office Equipment Gross OfficeEquipmentGross	57781
CY2022Q1	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	5607
CY2021Q2	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	5607
CY2022Q1	us-gaap	Fixtures And Equipment Gross FixturesAndEquipmentGross	6109848
CY2021Q2	us-gaap	Fixtures And Equipment Gross FixturesAndEquipmentGross	5989807
CY2021Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	14333666
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5777932
	us-gaap	Depreciation Depreciation	522172
CY2021Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5248765
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8804720
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9084901
CY2022Q1	us-gaap	Depreciation Depreciation	179492
CY2021Q1	us-gaap	Depreciation Depreciation	174076
	us-gaap	Depreciation Depreciation	529167
CY2022Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	458954
CY2021Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	458954
CY2022Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	115038
CY2021Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	108836
CY2022Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	343916
CY2021Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	350118
CY2022Q1	us-gaap	Adjustment For Amortization AdjustmentForAmortization	2067
CY2021Q1	us-gaap	Adjustment For Amortization AdjustmentForAmortization	2067
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	6202
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	6202
CY2022Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	234198
CY2021Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	235476
CY2022Q1	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	23932
CY2021Q1	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	24062
CY2022Q1	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0474
CY2021Q1	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.05
CY2022Q1	us-gaap	Loans Payable LoansPayable	164905
CY2021Q2	us-gaap	Loans Payable LoansPayable	95306
CY2022Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	2502
	us-gaap	Interest Expense Debt InterestExpenseDebt	3282
	us-gaap	Interest Expense Debt InterestExpenseDebt	3445
CY2021Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	2516
	nnvc	Ratio Of Converted Value To Common RatioOfConvertedValueToCommon	0.035
	nnvc	Employment Agreement Term EmploymentAgreementTerm	P3Y

Files In Submission

Name	View Source	Status
0001410578-22-001688-index-headers.html	Edgar Link	pending
0001410578-22-001688-index.html	Edgar Link	pending
0001410578-22-001688.txt	Edgar Link	pending
0001410578-22-001688-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nnvc-20220331.xsd	Edgar Link	pending
nnvc-20220331x10q.htm	Edgar Link	pending
nnvc-20220331x10q_htm.xml	Edgar Link	completed
nnvc-20220331xex31d1.htm	Edgar Link	pending
nnvc-20220331xex31d2.htm	Edgar Link	pending
nnvc-20220331xex32d1.htm	Edgar Link	pending
nnvc-20220331xex32d2.htm	Edgar Link	pending
nnvc-20220331_cal.xml	Edgar Link	unprocessable
nnvc-20220331_def.xml	Edgar Link	unprocessable
nnvc-20220331_lab.xml	Edgar Link	unprocessable
nnvc-20220331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NNVC
NANOVIRICIDES, INC. Stock $nnvc

2022 Q2 Form 10-Q Financial Statement

#000141057822001688 Filed on May 16, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NNVC NANOVIRICIDES, INC. Stock $nnvc

2022 Q2 Form 10-Q Financial Statement

#000141057822001688 Filed on May 16, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NNVC
NANOVIRICIDES, INC. Stock $nnvc